Abstract
11C-Pittsburgh compound B (PiB) uptake in PET images is frequently used to analyze β amyloid (Aβ) deposition in living individuals, but its correlation with histologically determined Aβ has not been examined. Six individuals with dementia underwent PiB-PET imaging, and their brains were analyzed neuropathologically (mean interval between imaging and death: 816 days; PiB positive:negative, 3:3; male:female, 3:3; mean age: 84.0 years). PiB uptake (reported as standardized uptake value ratio [SUVR]) was analyzed in 11 cortical regions and 10 subcortical grey matter areas and compared with the Aβ load (% area [the percentage of total area positive for Aβ] and number of neuritic plaques) seen with immunohistochemical staining with an anti-Aβ 11-28 antibody. Two PiB-positive subjects had abundant neuritic plaques and were diagnosed with Alzheimer’s disease (AD). SUVR and % area were strongly correlated in the cortical regions of these subjects (subject 1: r = 0.65, p = 0.03; subject 2: r = 0.80, p = 0.003). The other PiBpositive subject (subject 3) showed focal PiB uptake. In subject 3 and the 3 PiB-negative subjects (subjects 4-6), there was no correlation between regional SUVR and % area or neuritic plaques. PiB uptake was not correlated with Aβ deposition in subcortical regions. High PiB positivity in the cerebral cortex suggests the presence of substantial Aβ deposition and neuritic plaques associated with the pathologic changes of AD. Our results suggest that high cortical SUVR is a reliable marker of AD. Subcortical PiB positivity must be interpreted more carefully.
Keywords: Alzheimer’s disease, amyloid beta protein, autopsy, 11C-Pittsburgh compound B (PiB), positron emission tomography (PET), senile plaques.
Current Alzheimer Research
Title:Amyloid β Accumulation Assessed with 11C-Pittsburgh Compound B PET and Postmortem Neuropathology
Volume: 12 Issue: 3
Author(s): Hiroyuki Hatsuta, Masaki Takao, Kenji Ishii, Kiichi Ishiwata, Yuko Saito, Kazutomi Kanemaru, Tomio Arai, Tetsuya Suhara, Hitoshi Shimada, Hitoshi Shinotoh, Akira Tamaoka and Shigeo Murayama
Affiliation:
Keywords: Alzheimer’s disease, amyloid beta protein, autopsy, 11C-Pittsburgh compound B (PiB), positron emission tomography (PET), senile plaques.
Abstract: 11C-Pittsburgh compound B (PiB) uptake in PET images is frequently used to analyze β amyloid (Aβ) deposition in living individuals, but its correlation with histologically determined Aβ has not been examined. Six individuals with dementia underwent PiB-PET imaging, and their brains were analyzed neuropathologically (mean interval between imaging and death: 816 days; PiB positive:negative, 3:3; male:female, 3:3; mean age: 84.0 years). PiB uptake (reported as standardized uptake value ratio [SUVR]) was analyzed in 11 cortical regions and 10 subcortical grey matter areas and compared with the Aβ load (% area [the percentage of total area positive for Aβ] and number of neuritic plaques) seen with immunohistochemical staining with an anti-Aβ 11-28 antibody. Two PiB-positive subjects had abundant neuritic plaques and were diagnosed with Alzheimer’s disease (AD). SUVR and % area were strongly correlated in the cortical regions of these subjects (subject 1: r = 0.65, p = 0.03; subject 2: r = 0.80, p = 0.003). The other PiBpositive subject (subject 3) showed focal PiB uptake. In subject 3 and the 3 PiB-negative subjects (subjects 4-6), there was no correlation between regional SUVR and % area or neuritic plaques. PiB uptake was not correlated with Aβ deposition in subcortical regions. High PiB positivity in the cerebral cortex suggests the presence of substantial Aβ deposition and neuritic plaques associated with the pathologic changes of AD. Our results suggest that high cortical SUVR is a reliable marker of AD. Subcortical PiB positivity must be interpreted more carefully.
Export Options
About this article
Cite this article as:
Hatsuta Hiroyuki, Takao Masaki, Ishii Kenji, Ishiwata Kiichi, Saito Yuko, Kanemaru Kazutomi, Arai Tomio, Suhara Tetsuya, Shimada Hitoshi, Shinotoh Hitoshi, Tamaoka Akira and Murayama Shigeo, Amyloid β Accumulation Assessed with 11C-Pittsburgh Compound B PET and Postmortem Neuropathology, Current Alzheimer Research 2015; 12 (3) . https://dx.doi.org/10.2174/1567205012666150302155930
DOI https://dx.doi.org/10.2174/1567205012666150302155930 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Mixed Connective Tissue Disease (MCTD) – A Coming of Age
Current Rheumatology Reviews Intestinal Parasite Infestation in HIV Infected Patients
Current HIV Research Autoimmune Neuromuscular Disorders
Current Neuropharmacology Patent Selections:
Recent Patents on Regenerative Medicine More Effective DPP4 Inhibitors as Antidiabetics Based on Sitagliptin Applied QSAR and Clinical Methods
Current Computer-Aided Drug Design Antioxidants and Neuroprotection in the Adult and Developing Central Nervous System
Current Medicinal Chemistry Small Molecule Hydrazide Agents to Inhibit Growth and Proliferation of Mycobacterium Tuberculosis
Medicinal Chemistry Tandem Multicomponent Reactions Toward the Design and Synthesis of Novel Antibacterial and Cytotoxic Motifs
Current Medicinal Chemistry Viral Myocarditis and Dilated Cardiomyopathy: Etiology and Pathogenesis
Current Pharmaceutical Design Significant Breakthroughs in Search for Anti-Infectious Agents Derived from Erythromycin A
Current Medicinal Chemistry Therapeutic Options for the Treatment of 2019-Novel Coronavirus in India: A Review
Coronaviruses Medical Applications of Implantable Drug Delivery Microdevices Based on MEMS (Micro-Electro-Mechanical-Systems)
Current Pharmaceutical Biotechnology Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Kynurenine Pathway in Schizophrenia: Pathophysiological and Therapeutic Aspects
Current Pharmaceutical Design The Multifaceted Activities of Mammalian Defensins
Current Pharmaceutical Design Drug-Induced Aseptic Meningitis
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Progenitor Cell Types in HIV-1 Infection: Bioactivity and Emerging Targets for Treatment
Current HIV Research Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy N-Terminal Pro-C-Type Natriuretic Peptide: The Novel Marker in Selected Disease Units
Protein & Peptide Letters Chemotherapy Delivery Strategies to the Central Nervous System: neither Optional nor Superfluous
Current Cancer Drug Targets